BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33489471)

  • 1. Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study).
    Cheng S; Zhong W; Xia K; Hong P; Lin R; Wang B; Li X; Chen J; Liu Z; Zhang H; Liu C; Ye L; Ma L; Lin T; Li X; Huang J; Zhou L
    Oncoimmunology; 2021 Jan; 10(1):1861737. PubMed ID: 33489471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
    Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
    Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features.
    Bai Y; Wu X; Weng M; Han Q; Xu L; Chang C; Teng X
    Indian J Pathol Microbiol; 2023; 66(4):702-707. PubMed ID: 38084519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Lymphadenectomy During Radical Nephroureterectomy in Locally Advanced Upper Tract Urothelial Carcinoma.
    Ikeda M; Matsumoto K; Sakaguchi K; Ishii D; Tabata KI; Kurosawa K; Urakami S; Okaneya T; Iwamura M
    Clin Genitourin Cancer; 2017 Oct; 15(5):556-562. PubMed ID: 28501481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis.
    Lu Y; Kang J; Luo Z; Song Y; Tian J; Li Z; Wang X; Liu L; Yang Y; Liu X
    Front Oncol; 2020; 10():1400. PubMed ID: 32974145
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laparoscopic versus open nephroureterectomy to treat localized and/or locally advanced upper tract urothelial carcinoma: oncological outcomes from a multicenter study.
    Liu JY; Dai YB; Zhou FJ; Long Z; Li YH; Xie D; Liu B; Tang J; Tan J; Yao K; He LY
    BMC Surg; 2017 Jan; 17(1):8. PubMed ID: 28095848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Preoperative Albumin-Globulin Ratio on Oncologic Outcomes in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
    Xu H; Tan P; Ai J; Huang Y; Lin T; Yang L; Wei Q
    Clin Genitourin Cancer; 2018 Oct; 16(5):e1059-e1068. PubMed ID: 29980449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy.
    Shibing Y; Turun S; Qiang W; Junhao L; Haichao Y; Shengqiang Q; Ping H; Dehong C
    Urol Oncol; 2015 May; 33(5):204.e9-16. PubMed ID: 25800374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma.
    Okuda Y; Kato T; Fujita K; Fushimi H; Miyamoto H; Netto GJ; Nonomura N
    Cancer Genomics Proteomics; 2024; 21(2):137-143. PubMed ID: 38423597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy.
    Sikic D; Weyerer V; Geppert CI; Bertz S; Lange F; Taubert H; Wach S; Schmitz-Draeger BJ; Wullich B; Hartmann A; Eckstein M
    Urol Oncol; 2022 Feb; 40(2):63.e19-63.e26. PubMed ID: 34420870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumour-associated stroma correlates with poor clinical outcomes and immunoevasive contexture in patients with upper tract urothelial carcinoma: results from a multicenter real-world study (TSU-01 Study).
    Xu L; Zhong W; Li C; Hong P; Xia K; Lin R; Cheng S; Wang B; Yang M; Chen J; Ma L; Li X; Zhou L; Huang J; Lin T
    Br J Cancer; 2023 Jan; 128(2):310-320. PubMed ID: 36396819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.
    Zhang B; Yu W; Feng X; Zhao Z; Fan Y; Meng Y; Hu S; Cui Y; He Q; Zhang H; Li D; He Z; Zhou L; Jin J; Han W
    Med Oncol; 2017 May; 34(5):94. PubMed ID: 28409437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
    Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
    Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
    Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
    World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation analysis of PD-L1 expression and prognosis in triple-negative breast cancers].
    Pan BJ; Xu C; Ping GQ; Song GX; Zhang WM; Wang C; Zhang ZH
    Zhonghua Bing Li Xue Za Zhi; 2017 Dec; 46(12):822-826. PubMed ID: 29224274
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma.
    Campedel L; Compérat E; Cancel-Tassin G; Varinot J; Pfister C; Delcourt C; Gobet F; Roumiguié M; Patard PM; Daniel G; Bigot P; Carrouget J; Eymerit C; Larré S; Léon P; Durlach A; Ruffion A; de Mazancourt ES; Decaussin-Petrucci M; Bessède T; Lebacle C; Ferlicot S; Robert G; Vuong NS; Philip M; Crouzet S; Matillon X; Mège-Lechevallier F; Lang H; Mouracade P; Lindner V; Gougis P; Cussenot O; Rouprêt M; Seisen T
    BJU Int; 2023 Nov; 132(5):581-590. PubMed ID: 37488983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
    Lien HC; Lee YH; Chen IC; Lin CH; Chen TW; Lu YT; Lu YS
    Virchows Arch; 2021 Apr; 478(4):669-678. PubMed ID: 33089401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.